[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100643815":3},{"organization":4,"armGroups":7,"interventions":25,"overallOfficials":11,"centralContacts":37,"locations":43,"responsibleParty":59,"collaborators":11,"id":61,"slug":62,"hasResults":63,"nctId":64,"briefTitle":65,"officialTitle":66,"acronym":11,"eligibilityCriteria":67,"healthyVolunteers":68,"sex":69,"minAge":70,"maxAge":71,"enrollmentInfo":72,"targetDuration":11,"studyType":75,"phases":76,"briefSummary":78,"conditions":79,"keywords":11,"overallStatus":46,"whyStopped":11,"lastUpdateSubmitDate":81,"lastUpdatePostDateStruct":82,"startDateStruct":85,"completionDateStruct":87,"leadSponsor":88,"locationsCount":89},{"fullName":5,"class":6},"Dong-A ST Co., Ltd.","INDUSTRY",[8,15,18,22],{"label":9,"type":10,"description":11,"interventionNames":12},"Sequence A","EXPERIMENTAL",null,[13,14],"Drug: DA-5223-R","Drug: DA-5223-F",{"label":16,"type":10,"description":11,"interventionNames":17},"Sequence B",[13,14],{"label":19,"type":10,"description":11,"interventionNames":20},"Sequence C",[13,21],"Drug: DA-5223-M",{"label":23,"type":10,"description":11,"interventionNames":24},"Sequence D",[13,21],[26,31,34],{"type":27,"name":28,"description":29,"armGroupLabels":30,"otherNames":11},"DRUG","DA-5223-R","once a day",[9,16,19,23],{"type":27,"name":32,"description":29,"armGroupLabels":33,"otherNames":11},"DA-5223-F",[9,16],{"type":27,"name":35,"description":29,"armGroupLabels":36,"otherNames":11},"DA-5223-M",[19,23],[38],{"name":39,"role":40,"phone":41,"phoneExt":11,"email":42},"Taegon Hong","CONTACT","82-02-2620-0251","tghong@bumin.co.kr",[44],{"facility":45,"status":46,"city":47,"state":48,"zip":49,"country":50,"countryCode":11,"cosmosGeoPoint":51,"geoPoint":56,"contacts":57},"Bumin hospital","RECRUITING","Gangseo-gu","Seoul","07590","South Korea",{"type":52,"coordinates":53},"Point",[54,55],126.82139,37.56333,{"lat":55,"lon":54},[58],{"name":45,"role":40,"phone":41,"phoneExt":11,"email":42},{"type":60,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100643815","phase-1-a-study-to-exploratively-evaluate-the-safety-tolerability-and-pharmacokinetics-of-da-5223-compared-with-da-5223-r-in-healthy-adult-subjects-100643815",false,"NCT07633691","A Study to Exploratively Evaluate the Safety, Tolerability and Pharmacokinetics of DA-5223 Compared With DA-5223-R in Healthy Adult Subjects","An Open-label, Randomized, Single-dose, Two-Cohort, Two-Period, Crossover Study to Exploratively Evaluate the Safety, Tolerability and Pharmacokinetics of DA-5223 Compared With DA-5223-R in Healthy Adult Subjects","Inclusion Criteria:\n\n* Adult male or female, 19 years to 55 years\n* Male weighing 50 kg or more, female weighing 45 kg or more with a body mass index (BMI) of 18.0 kg\u002Fm2 to 30.0 kg\u002Fm2\n* The subjects signed and dated informed consent form after hearing a detailed explanation of the study, fully understanding and determined voluntarily to participate\n\nExclusion Criteria:\n\n* The subjects with acute illness\n* The subjects with a history of gastrointestinal disease or surgery that may affect the absorption of Investigational Product\n* The subjects hypersensitive to any of the Investigational Product components or other drug components\n* The subjects who have continuously consumed excessive smoking or alcohol within 1 months of screening, or who cannot stop smoking, caffeine, or alcohol intake during hospitalization\n* The subjects who are pregnant or lactating",true,"ALL","19 Years","55 Years",{"count":73,"type":74},12,"ESTIMATED","INTERVENTIONAL",[77],"PHASE1","This study will exploratively evaluate the safety, tolerability and pharmacokinetics of DA-5223 compared with DA-5223-R in healthy adult subjects",[80],"Healthy Adult","2026-06-04",{"date":83,"type":84},"2026-06-08","ACTUAL",{"date":86,"type":74},"2026-06",{"date":86,"type":74},{"name":5,"class":6},1]